Tyra Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tyra Biosciences, Inc. (Nasdaq: TYRA) on November 25, 2025. The report discloses executive leadership changes effective December 1, 2025, specifically the appointment of a new Chief Operating Officer and the reassignment of the previous COO.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Executive Appointment: Bhavesh Ashar was appointed Chief Operating Officer (COO), succeeding Daniel Bensen.
- Executive Reassignment: Daniel Bensen was appointed Chief Discovery Officer.
- Effective Date: Both changes are effective December 1, 2025.
Management Commentary, Risks, and Unusual Items
The filing details the employment agreement for Mr. Ashar, including:
- Compensation: Initial annual base salary of $550,000 with a target annual incentive of 40% of base salary.
- Equity Grant: Options to purchase 300,000 shares of common stock, vesting over four years (25% on the first anniversary, remainder monthly).
- Severance Provisions:
- Outside Change in Control: 12 months of base salary plus pro-rated bonus, 50% equity acceleration, and 12 months of COBRA coverage upon termination without cause, death, disability, or resignation for good reason.
- Within Change in Control Period: 18 months of base salary plus target bonus, 100% equity acceleration, and 12 months of COBRA coverage.
The filing notes that the full employment agreement will be filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2025.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 300,000 stock options for Mr. Ashar in the upcoming Form 10-K.
- Review the full text of the Employment Agreement to confirm specific definitions of "good reason" and "change in control."
- Monitor future filings for Daniel Bensen's new compensation package as Chief Discovery Officer.
- Assess the impact of the leadership transition on the company's commercial strategy and discovery pipeline.